NEFL and myeloid sarcoma: The proportions of patients with MS progression or activity during the year prior to their inclusion were identical in the 3 groups of the trial and their previous treatments’ repertoire, similar12, excluding therefore the possibility that the observed changes in NF-L levels could be attributed to differences between the study groups in these parameters.